Taking people in South KoreaNo phase
LAG-3 protein and chemotherapy with immune therapy in triple negative breast cancer
Studies LAG-3 protein in people with triple negative breast cancer.
Plain-language title generated from the registry record
Registry title: LAG3 Expression in Triple Negative Breast Cancer
Key facts
- Where
- Seoul, South KoreaSee the site
Where in South Korea
- Ji-Yeon KimSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Samsung Medical Center
- Trial code
- NCT06259162
- Record updated
- 14 February 2024
- Original description
This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.Read full original descriptionShow less
The Evaluation the Relationship Between LAG-3 Expression / Immune Checkpoint Protein Expression and Neoadjuvant Chemotherapy Plus Immune Checkpoint Inhibitor in Triple Negative Breast Cancer
This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.
Inclusion: Planned neoadjuvant chemotherapy; Triple negative breast cancer.
Exclusion: HER2-positive breast cancer; Hormone receptor positive breast cancer.